Previous 10 | Next 10 |
ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...
ChemoCentryx ([[CCXI]]) has detailed the full outcome of the FDA’s Adcom meeting on avacopan for the treatment of vasculitis associated with antineutrophil cytoplasmic autoantibody ((ANCA)) (or AAV).The committee vote was split (9-9) on the first question: ‘whether the...
SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil C...
The FDA's Arthritis Advisory Committee voted down the middle, 9-9, on whether Chemocentryx's (CCXI) avacopan for vasculitis demonstrated sufficient efficacy evidence to support approval.An FDA briefing document released two days before today's meeting raised issues with the company's clinical...
Esperion Therapeutics (ESPR) -32% on Q1 earnings release.Cocrystal Pharma (COCP) -27% after launches $40M stock offering.SemiLEDs (LEDS) -21%.Mercury Systems (MRCY) -18% on FQ3 earnings release.Adamis Pharmaceuticals (ADMP) -14%.Reed's (REED) -14% after...
SAN FRANCISCO, May 04, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now . The firm is investigating possible securities law violations and certain investors may have valuable claims. Visi...
Shares of ChemoCentryx (NASDAQ: CCXI) were crashing 46.5% lower as of 3:06 p.m. EDT on Tuesday. The huge decline came after the U.S. Food and Drug Administration (FDA) released briefing documents for an advisory committee scheduled to meet on Thursday to review the approval applicat...
Gainers: Cocrystal Pharma (COCP) +157%.BioLineRx (BLRX) +75%.Reed's (REED) +36%.Neuronetics (STIM) +25%.Shineco (TYHT) +24%.Domtar (UFS) +18%.Arconic (ARNC) +17%.Huttig Building Products (HBP) +15%.Village Bank and Trust Financial (VBFC) +15%.Precipio (PRPO) +13%.Losers: ChemoC...
Chemocentryx (CCXI) shares are down more than 42% after an FDA briefing document indicates the agency has "several areas of concerns" with its vasculitis candidate avacopan.The FDA's Arthritis Drugs Advisory Committee will discuss the candidate on Thursday.In particular, FDA reviewers cited "...
Gainers: Cocrystal Pharma (COCP) +97%, BioLineRx (BLRX) +51%, Neuronetics (STIM) +21%, Shineco (TYHT) +20%, Precipio (PRPO) +14%.Losers: ChemoCentryx (CCXI) -38%, Regional Health Properties (RHE) -35%, Brooklyn ImmunoTherapeutics (BTX) -3...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...